17.345 USD
+0.02 (+0.14%)
Taking everything into account, KROS scores 6 out of 10 in our fundamental rating. KROS was compared to 533 industry peers in the Biotechnology industry. KROS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KROS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
KROS had positive earnings in the past year.
In the past year KROS had a positive cash flow from operations.
KROS had negative earnings in each of the past 5 years.
KROS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of KROS (8.68%) is better than 93.62% of its industry peers.
With an excellent Return On Equity value of 9.16%, KROS belongs to the best of the industry, outperforming 93.25% of the companies in the same industry.
KROS's Return On Invested Capital of 4.79% is amongst the best of the industry. KROS outperforms 91.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 9.16% | ||
| ROIC | 4.79% |
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KROS has a Profit Margin of 26.12%. This is amongst the best in the industry. KROS outperforms 95.50% of its industry peers.
KROS has a Operating Margin of 17.67%. This is amongst the best in the industry. KROS outperforms 94.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.67% | ||
| PM (TTM) | 26.12% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KROS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
KROS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KROS has been increased compared to 5 years ago.
There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 11.55 indicates that KROS is not in any danger for bankruptcy at the moment.
KROS's Altman-Z score of 11.55 is amongst the best of the industry. KROS outperforms 84.24% of its industry peers.
There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.55 |
ROIC/WACC0.55
WACC8.68%
2.3 Liquidity
A Current Ratio of 29.86 indicates that KROS has no problem at all paying its short term obligations.
The Current ratio of KROS (29.86) is better than 98.31% of its industry peers.
A Quick Ratio of 29.86 indicates that KROS has no problem at all paying its short term obligations.
The Quick ratio of KROS (29.86) is better than 98.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 29.86 | ||
| Quick Ratio | 29.86 |
3. Growth
3.1 Past
KROS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 129.56%, which is quite impressive.
KROS shows a strong growth in Revenue. In the last year, the Revenue has grown by 37798.31%.
KROS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.71% yearly.
EPS 1Y (TTM)129.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.23%
Revenue 1Y (TTM)37798.31%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%3575.77%
3.2 Future
The Earnings Per Share is expected to grow by 10.26% on average over the next years. This is quite good.
The Revenue is expected to grow by 178.15% on average over the next years. This is a very strong growth
EPS Next Y118.16%
EPS Next 2Y5.16%
EPS Next 3Y3.86%
EPS Next 5Y10.26%
Revenue Next Year39294.7%
Revenue Next 2Y325.62%
Revenue Next 3Y182.51%
Revenue Next 5Y178.15%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.26, which indicates a very decent valuation of KROS.
KROS's Price/Earnings ratio is rather cheap when compared to the industry. KROS is cheaper than 97.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.98, KROS is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for KROS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.26 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, KROS is valued cheaply inside the industry as 99.62% of the companies are valued more expensively.
KROS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KROS is cheaper than 98.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.09 | ||
| EV/EBITDA | 0.22 |
4.3 Compensation for Growth
KROS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.1
PEG (5Y)N/A
EPS Next 2Y5.16%
EPS Next 3Y3.86%
5. Dividend
5.1 Amount
KROS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KROS (11/26/2025, 1:02:07 PM)
17.345
+0.02 (+0.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.17%
Inst Owner Change-1.67%
Ins Owners1.24%
Ins Owner Change4.74%
Market Cap704.55M
Revenue(TTM)246.72M
Net Income(TTM)64.45M
Analysts78.82
Price Target23.72 (36.75%)
Short Float %15.24%
Short Ratio6.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.66%
Min EPS beat(2)34.17%
Max EPS beat(2)83.15%
EPS beat(4)3
Avg EPS beat(4)416.03%
Min EPS beat(4)-13.69%
Max EPS beat(4)1560.5%
EPS beat(8)6
Avg EPS beat(8)209.12%
EPS beat(12)9
Avg EPS beat(12)139.65%
EPS beat(16)11
Avg EPS beat(16)109.44%
Revenue beat(2)2
Avg Revenue beat(2)405.88%
Min Revenue beat(2)267.96%
Max Revenue beat(2)543.8%
Revenue beat(4)3
Avg Revenue beat(4)2529.19%
Min Revenue beat(4)-80.66%
Max Revenue beat(4)9385.68%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.09%
PT rev (3m)1.09%
EPS NQ rev (1m)32.52%
EPS NQ rev (3m)38.24%
EPS NY rev (1m)0%
EPS NY rev (3m)1978.36%
Revenue NQ rev (1m)-3.6%
Revenue NQ rev (3m)68.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)18.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.26 | ||
| Fwd PE | N/A | ||
| P/S | 2.86 | ||
| P/FCF | 8.09 | ||
| P/OCF | 7.94 | ||
| P/B | 1 | ||
| P/tB | 1 | ||
| EV/EBITDA | 0.22 |
EPS(TTM)1.54
EY8.88%
EPS(NY)-4.48
Fwd EYN/A
FCF(TTM)2.14
FCFY12.36%
OCF(TTM)2.19
OCFY12.6%
SpS6.07
BVpS17.32
TBVpS17.32
PEG (NY)0.1
PEG (5Y)N/A
Graham Number24.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 9.16% | ||
| ROCE | 6.06% | ||
| ROIC | 4.79% | ||
| ROICexc | 136.53% | ||
| ROICexgc | 136.53% | ||
| OM | 17.67% | ||
| PM (TTM) | 26.12% | ||
| GM | N/A | ||
| FCFM | 35.3% |
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 118.39% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 197.2% | ||
| Profit Quality | 135.12% | ||
| Current Ratio | 29.86 | ||
| Quick Ratio | 29.86 | ||
| Altman-Z | 11.55 |
F-Score8
WACC8.68%
ROIC/WACC0.55
Cap/Depr(3y)214.84%
Cap/Depr(5y)203.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)129.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.23%
EPS Next Y118.16%
EPS Next 2Y5.16%
EPS Next 3Y3.86%
EPS Next 5Y10.26%
Revenue 1Y (TTM)37798.31%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%3575.77%
Revenue Next Year39294.7%
Revenue Next 2Y325.62%
Revenue Next 3Y182.51%
Revenue Next 5Y178.15%
EBIT growth 1Y121.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.84%
EBIT Next 3Y16.61%
EBIT Next 5YN/A
FCF growth 1Y170.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y173.69%
OCF growth 3YN/A
OCF growth 5YN/A
KEROS THERAPEUTICS INC / KROS FAQ
What is the ChartMill fundamental rating of KEROS THERAPEUTICS INC (KROS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to KROS.
Can you provide the valuation status for KEROS THERAPEUTICS INC?
ChartMill assigns a valuation rating of 5 / 10 to KEROS THERAPEUTICS INC (KROS). This can be considered as Fairly Valued.
What is the profitability of KROS stock?
KEROS THERAPEUTICS INC (KROS) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for KROS stock?
The Price/Earnings (PE) ratio for KEROS THERAPEUTICS INC (KROS) is 11.26 and the Price/Book (PB) ratio is 1.